Mouse models of thrombosis: Thrombomodulin

Thrombosis and Haemostasis

Volumn 92, Issue 3, 2004, Pages 467-477

  Weiler, Hartmut ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Mouse models; Protein C; Thrombomodulin

Indexed keywords

ANTICOAGULANT AGENT; PROTEIN C; THROMBIN; THROMBOMODULIN; ANTICOAGULANT PROTEIN;

ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; DATA ANALYSIS; DISEASE SEVERITY; DNA MODIFICATION; ENVIRONMENTAL FACTOR; ENZYME ACTIVATION; FIBRINOLYSIS; GENE LOCUS; HEMOSTASIS; HEREDITY; MOUSE MUTANT; MOUSE STRAIN; NONHUMAN; PHENOTYPE; PLACENTA CIRCULATION; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; REVIEW; SITE DIRECTED MUTAGENESIS; THROMBOPHILIA; THROMBOSIS; BREEDING; CELL TYPE; DISEASE COURSE; DISSEMINATED INTRAVASCULAR CLOTTING; GENE EXPRESSION; GENOTYPE ENVIRONMENT INTERACTION; MOUSE; PATHOLOGY; PLACENTA DEVELOPMENT; PROTEIN STRUCTURE; VALIDATION PROCESS; VASCULAR ENDOTHELIUM;

ANIMALS; CEREBROVASCULAR ACCIDENT; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; FEMALE; MICE; PLACENTA; PREGNANCY; PROTEIN C; THROMBOMODULIN; THROMBOSIS;

EID: 12344277910     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH04-05-0307     Document Type: Review

References (87)

1. Dittman WA, Majerus PW. Structure and function of thrombomodulin: a natural anticoagulant. Blood 1990; 75: 329-36.
2. Sadler JE. Thrombomodulin structure and function. Thromb Haemost 1997; 78: 392-5.
3. Esmon CT, Gu JM, Xu J, et al. Regulation and functions of the protein C anticoagulant pathway. Haematologica 1999; 84: 363-8.
4. Esmon CT. The normal role of Activated Protein C in maintaining homeostasis and its relevance to critical illness. Crit Care 2001; 5: S7-S12.
5. Taylor FB, Jr., Peer GT, Lockhart MS, et al. Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood 2001; 97: 1685-8.
6. Xu J, Esmon NL, Esmon CT. Reconstitution of the human endothelial cell protein C receptor with thrombomodulin in phosphatidylcholine vesicles enhances protein C activation. J Biol Chem 1999; 274: 6704-10.
7. Crawley JT, Gu JM, Ferrell G, et al. Distribution of endothelial cell protein C/activated protein C receptor (EPCR) during mouse embryo development. Thromb Haemost 2002; 88: 259-66.
8. Laszik Z, Mitro A, Taylor FB, Jr., et al. Human protein C receptor is present primarily on endothelium, of large blood vessels: implications for the control of the protein C pathway. Circulation 1997; 96: 3633-40.
9. Broze GJ, Jr., Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 1996; 88: 3815-23.
10. Nesheim M, Wang W, Boffa M, et al. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 1997; 78: 386-91.
11. Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 2000; 20: 2511-8.
12. Myles T, Nishimura T, Yun TH, et al. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003; 278: 51059-67.
13. Campbell W, Okada N, Okada H. Carboxy-peptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis. Immunol Rev 2001; 180: 162-7.
14. Campbell WD, Lazoura E, Okada N, et al. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol 2002; 46: 131-4.
15. Riewald M, Petrovan RJ, Donner A, et al. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002; 296: 1880-2.
16. Riewald M, Ruf W. Orchestration of coagulation protease signaling by tissue factor. Trends Cardiovasc Med 2002; 12: 149-54.
17. Jackman RW, Beeler DL, VanDeWater L, et al. Characterization of a thrombomodulin cDNA reveals structural similarity to the low density lipoprotein receptor. Proc Natl Acad Sci U S A 1986; 83: 8834-8.
18. Wood MJ, Sampoli Benitez BA, et al. Solution structure of the smallest cofactor-active fragment of thrombomodulin. Nat Struct Biol 2000; 7: 200-4.
19. Fuentes-Prior P, Iwanaga Y, Huber R, et al. Structural basis for the anticoagulant activity of the thrombin- thrombomodulin complex. Nature 2000; 404: 518-25.
20. Christian S, Ahorn H, Koehler A, et al. Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium. J Biol Chem 2001; 276: 7408-14.
21. Petersen TE. The amino-terminal domain of thrombomodulin and pancreatic stone protein are homologous with lectins. FEBS Lett 1988; 231: 51-3.
22. Dean YD, McGreal EP, Akatsu H, et al. Molecular and cellular properties of the rat AA4 antigen, a C-type lectin-like receptor with structural homology to thrombomodulin. J Biol Chem 2000; 275: 34382-92.
23. Conway EM, Pollefeyt S, Collen D, et al. The amino terminal lectin-like domain of thrombomodulin is required for constitutive endocytosis. Blood 1997; 89: 652-61.
24. Zhang Y, Weiler-Guettler H, Chen J, et al. Thrombomodulin modulates growth of tumor cells independent of its anticoagulant activity. J Clin Invest 1998; 101: 1301-9.
25. Conway EM, Van de Wouwer M, Pollefeyt S, et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med 2002; 196: 565-77.
26. Weisel JW, Nagaswami C, Young TA, et al. The shape of thrombomodulin and interactions with thrombin as determined by electron microscopy. J Biol Chem 1996; 271: 31485-90.
27. Bourin MC, Boffa MC, Bjork I, et al. Functional domains of rabbit thrombomodulin. Proc Natl Acad Sci U S A 1986; 83: 5924-8.
28. Bourin MC, Lundgren-Akerlund E, Lindahl U. Isolation and characterization of the glycosaminoglycan component of rabbit thrombomodulin proteoglycan. J Biol Chem 1990; 265: 15424-31.
29. Sadler JE, Lentz SR, Sheehan JP, et al. Structure-function relationships of the thrombin-thrombomodulin interaction. Haemostasis 1993; 23 Suppl 1: 183-93.
30. Tsiang M, Lentz SR, Sadler JE. Functional domains of membrane-bound human thrombomodulin. EGF-like domains four to six and the serine/threonine-rich domain are required for cofactor activity. J Biol Chem 1992; 267: 6164-70.
31. Kokame K, Zheng X, Sadler JE. Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C. J Biol Chem 1998; 273: 12135-9.
32. Leung LL, Hall SW. Dissociation of thrombin's substrate interactions using site-directed mutagenesis. Trends Cardiovasc Med 2000; 10: 89-92.
33. Hall SW, Nagashima M, Zhao L, et al. Thrombin interacts with thrombomodulin, protein C, and thrombin- activatable fibrinolysis inhibitor via specific and distinct domains. J Biol Chem 1999; 274: 25510-16.
34. Wang W, Nagashima M, Schneider M, et al. Elements of the primary structure of thrombomodulin required for efficient thrombin-activable fibrinolysis inhibitor activation. J Biol Chem 2000; 275: 22942-7.
35. Preissner KT, Koyama T, Muller D, et al. Domain structure of the endothelial cell receptor thrombomodulin as deduced from modulation of its anticoagulant functions. Evidence for a glycosaminoglycan-dependent secondary binding site for thrombin. J Biol Chem 1990; 265: 4915-22.
36. Ye J, Esmon CT, Johnson AE. The chondroitin sulfate moiety of thrombomodulin binds a second molecule of thrombin. J Biol Chem 1993; 268: 2373-9.
37. Rabhi-Sabile S, Steiner-Mosonyi M, Pollefeyt S, et al. Plasmodium falciparum-infected erythrocytes: a mutational analysis of cytoadherence via murine thrombomodulin. Thromb Haemost 1999; 81: 815-21.
38. Gysin J, Pouvelle B, Le Tonqueze M, et al. Chondroitin sulfate of thrombomodulin is an adhesion receptor for Plasmodium falciparum-infected erythrocytes. Mol Biochem Parasitol 1997; 88: 267-71.
39. Hamada H, Ishii H, Sakyo K, et al. The epidermal growth factor-like domain of recombinant human thrombomodulin exhibits mitogenic activity for Swiss 3T3 cells. Blood 1995; 86: 225-33.
40. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000; 95: 1517-32.
41. Hajjar KA. Factor V Leiden - an unselfish gene? N Engl J Med 1994; 331: 1585-7.
42. Majerus PW. Human genetics. Bad blood by mutation. Nature 1994; 369: 14-15.
43. Kerlin BA, Yan SB, Isermann BH, et al. Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood 2003; 102: 3085-92.
44. Kunz G, Ohlin AK, Adami A, et al. Naturally occurring mutations in the thrombomodulin gene leading to impaired expression and function. Blood 2002;9 9: 3646-53.
45. Salomaa V, Matei C, Aleksic N, et al. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. Lancet 1999; 353: 1729-34.
46. Healy AM, Rayburn HB, Rosenberg RD, et al. Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. Proc Natl Acad Sci USA 1995; 92: 850-4.
47. Weiler-Guettler H, Aird WC, Husain M, et al. Targeting of transgene expression to the vascular endothelium of mice by homologous recombination at the thrombomodulin locus. Circ Res 1996; 78: 180-7.
48. Weiler-Guettler H, Aird WC, Rayburn H, et al. Developmentally regulated gene expression of thrombomodulin in postimplantation mouse embryos. Development 1996; 122: 2271-81.
49. Isermann B, Hendrickson SB, Zogg M, et al. Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis. J Clin Invest 2001; 108: 537-46.
50. Weiler-Guettler H, Christie PD, Beeler DL, et al. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest 1998; 101: 1983-91.
51. Weiler H, Lindner V, Kerlin B, et al. Characterization of a mouse model for thrombomodulin deficiency. Arterioscler Thromb Vasc Biol 2001; 21: 1531-7.
52. Conway EM, Pollefeyt S, Cornelissen J, et al. Structure-function analyses of thrombomodulin by gene-targeting in mice: the cytoplasmic domain is not required for normal fetal development. Blood 1999; 93: 3442-50.
53. Norwitz ER, Schust DJ, Fisher SJ. Implantation and the survival of early pregnancy. N Engl J Med 2001; 345: 1400-8.
54. Rossant J, Cross JC. Placental development: lessons from mouse mutants. Nat Rev Genet 2001; 2: 538-48.
55. Rinkenberger J, Werb Z. The labyrinthine placenta. Nat Genet 2000; 25: 248-50.
56. Adamson SL, Lu Y, Whiteley KJ, et al. Interactions between trophoblast cells and the maternal and fetal circulation in the mouse placenta. Dev Biol 2002; 250: 358-73.
57. Pijnenborg R, Robertson WB, Brosens I, et al. Review article: trophoblast invasion and the establishment of haemochorial placentation in man and laboratory animals. Placenta 1981; 2: 71-91.
58. Isermann B, Hendrickson SB, Hutley K, et al. Tissue-restricted expression of thrombomodulin in the placenta rescues thrombomodulin-deficient mice from early lethality and reveals a secondary developmental block. Development 2001; 128: 827-38.
59. Isermann B, Sood R, Pawlinski R, et al. The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med 2003; 9: 331-7.
60. Preston FE, Rosendaal FR, Walker ID, et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348: 913-6.
61. Martinelli I, Taioli E, Cetin I, et al. Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med 2000; 343: 1015-8.
62. Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340: 9-13.
63. Franchi F, Biguzzi E, Cetin I, et al. Mutations in the thrombomodulin and endothelial protein C receptor genes in women with late fetal loss. Br J Haematol 2001; 114: 641-6.
64. Rey E, Kahn SR, David M, et al. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361: 901-8.
65. Cook CL, Pridham DD. Recurrent pregnancy loss. Curr Opin Obstet Gynecol 1995; 7: 357-66.
66. Younis JS, Samueloff A. Gestational vascular complications. Best Pract Res Clin Haematol 2003; 16: 135-51.
67. Eldor A. Thrombophilia, thrombosis and pregnancy. Thromb Haemost 2001; 86: 104-11.
68. Roberts D, Schwartz RS. Clotting and hemorrhage in the placenta - a delicate balance. N Engl J Med 2002; 347: 57-9.
69. Many A, Schreiber L, Rosner S, et al. Pathologic features of the placenta in women with severe pregnancy complications and thrombophilia. Obstet Gynecol 2001; 98: 1041-4.
70. Sikkema JM, Franx A, Bruinse HW, et al. Placental pathology in early onset pre-eclampsia and intra-uterine growth restriction in women with and without thrombophilia. Placenta 2002; 23: 337-42.
71. Mousa HA, Alfirevic Z. Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome? Hum Reprod 2000; 15: 1830-3.
72. Vern TZ, Alles AJ, Kowal-Vern A, et al. Frequency of factor V(Leiden) and prothrombin G20210A in placentas and their relationship with placental lesions. Hum Pathol 2000; 31: 1036-43.
73. Abbott BD, Buckalew AR. Placental defects in ARNT-knockout conceptus correlate with localized decreases in VEGF-R2, Ang-1, and Tie-2. Dev Dyn 2000; 219: 526-38.
74. Dunk C, Shams M, Nijjar S, et al. Angiopoietin-1 and angiopoietin-2 activate trophoblast Tie-2 to promote growth and migration during placental development. Am J Pathol 2000; 156: 2185-99.
75. Goldman-Wohl DS, Ariel I, Greenfield C, et al. Tie-2 and angiopoietin-2 expression at the fetal-maternal interface: a receptor ligand model for vascular remodelling. Mol Hum Reprod 2000; 6: 81-7.
76. Zhou Y, Fisher SJ, Janatpour M, et al. Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion? J Clin Invest 1997; 99: 2139-51.
77. Zhou Y, Damsky CH, Fisher SJ. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J Clin Invest 1997; 99: 2152-64.
78. Nagashima M, Yin ZF, Zhao L, et al. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 2002; 109: 101-10.
79. te Velde EA, Wagenaar GT, Reijerkerk A, et al. Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2003; 1: 2087-96.
80. Levi M, Dorffler-Melly J, Reitsma P, et al. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice. Blood 2003; 101: 4823-7.
81. Dorffler-Melly J, de Kruif M, Schwarte LA, et al. Functional thrombomodulin deficiency causes enhanced thrombus growth in a murine model of carotid artery thrombosis. Basic Res Cardiol 2003; 98: 347-52.
82. Healy AM, Hancock WW, Christie PD, et al. Intravascular coagulation activation in a murine model of thrombomodulin deficiency: effects of lesion size, age, and hypoxia on fibrin deposition. Blood 1998; 92: 4188-97.
83. Christie PD, Edelberg JM, Picard MH, et al. A murine model of myocardial microvascular thrombosis. J Clin Invest 1999; 104: 533-9.
84. Kerlin B, Cooley BC, Isermann BH, et al. Cause-effect relation between hyperfibrinogenemia and vascular disease. Blood 2004; 103: 1728-34.
85. Jalbert LR, Rosen ED, Moons L, et al. Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J Clin Invest 1998; 102: 1481-8.
86. Gu JM, Crawley JT, Ferrell G, et al. Disruption of the endothelial cell protein C receptor gene in mice causes placental thrombosis and early embryonic lethality. J Biol Chem 2002; 277: 43335-43.
87. Cui J, Eitzman DT, Westrick RJ, et al. Spontaneous thrombosis in mice carrying the factor V Leiden mutation. Blood 2000; 96: 4222-6.